Ionis posts presentation for 2026 annual shareholders meeting

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

IONS

0.00
  • Ionis shareholder meeting deck outlined a push to accelerate revenue growth toward sustained positive cash flow, targeting cash flow breakeven in 2028.
  • DAWNZERA U.S. net product sales reached $16 million in Q1 2026, up 128% from Q4 2025.
  • TRYNGOLZA U.S. net product sales totaled $27 million in Q1 2026, up 350% from Q1 2025; EU launch underway.
  • Olezarsen for severe hypertriglyceridemia received FDA priority review with a PDUFA date of June 30, 2026; peak annual revenue opportunity raised to more than $3 billion.
  • Zilganersen for Alexander disease received FDA priority review with a PDUFA date of Sept. 22, 2026; positioned as the first independent neurology launch expected in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.